Announcements
- Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
- Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
- Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
- Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
- Vivoryon Therapeutics N.V. Announces Changes to Board Composition
- Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
- Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
- Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
More ▼
Key statistics
On Friday, Vivoryon Therapeutics NV (05Y:DUS) closed at 2.60, 533.37% above the 52 week low of 0.4105 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.60 |
---|---|
High | 2.60 |
Low | 2.60 |
Bid | 2.45 |
Offer | 2.56 |
Previous close | 2.74 |
Average volume | 26.25k |
---|---|
Shares outstanding | 26.07m |
Free float | 17.35m |
P/E (TTM) | -- |
Market cap | 74.03m EUR |
EPS (TTM) | -1.13 EUR |
Data delayed at least 15 minutes, as of Jun 07 2024 07:11 BST.
More ▼